Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ATOS

Atossa Therapeutics (ATOS)

Atossa Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ATOS
DateTimeSourceHeadlineSymbolCompany
07/22/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
07/02/20244:15PMGlobeNewswire Inc.Atossa Therapeutics Appoints Heather Rees as Chief Financial OfficerNASDAQ:ATOSAtossa Therapeutics Inc
06/28/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
06/17/20248:30AMGlobeNewswire Inc.Atossa Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:ATOSAtossa Therapeutics Inc
06/05/20248:30AMGlobeNewswire Inc.Atossa to Present at the Sidoti Small-Cap Investor ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
05/28/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelNASDAQ:ATOSAtossa Therapeutics Inc
05/24/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATOSAtossa Therapeutics Inc
05/23/20249:00AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
05/15/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
05/14/20244:46PMEdgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:ATOSAtossa Therapeutics Inc
05/13/20244:05PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATOSAtossa Therapeutics Inc
05/13/20249:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATOSAtossa Therapeutics Inc
05/13/20249:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
05/13/20248:50AMGlobeNewswire Inc.Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
05/10/20249:04AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ATOSAtossa Therapeutics Inc
05/10/20249:00AMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
05/07/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesNASDAQ:ATOSAtossa Therapeutics Inc
04/29/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
04/15/20248:30AMGlobeNewswire Inc.Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
04/11/20248:30AMGlobeNewswire Inc.Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
04/09/202411:59AMGlobeNewswire Inc.Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
04/01/20244:00PMGlobeNewswire Inc.Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
03/19/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientNASDAQ:ATOSAtossa Therapeutics Inc
03/18/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsNASDAQ:ATOSAtossa Therapeutics Inc
03/12/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsNASDAQ:ATOSAtossa Therapeutics Inc
02/22/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyNASDAQ:ATOSAtossa Therapeutics Inc
02/07/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
01/09/20248:30AMGlobeNewswire Inc.Atossa Therapeutics Issues Letter to ShareholdersNASDAQ:ATOSAtossa Therapeutics Inc
12/04/20238:30AMGlobeNewswire Inc.Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNASDAQ:ATOSAtossa Therapeutics Inc
11/20/20238:30AMGlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATOS

Your Recent History

Delayed Upgrade Clock